Trials / Unknown
UnknownNCT04502355
Voriconazole-Induced QT Interval Prolongation: A Prospective Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- Rabin Medical Center · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- —
Summary
The antifungal voriconazole is effective for the treatment of invasive fungal infections in immunocompromised patients. A serious adverse reaction is QT interval prolongation, which may precede life-threatening arrhythmias, such as torsades de pointes. Although ventricular arrhythmias are mentioned as a possible adverse effect of voriconazole, thus far, the incidence and clear recommendations for QT follow-up have not been published. This prospective observational study aimed at describing the incidence of voriconazole induced- QT interval prolongation in the pediatric population and determine the risk factors for this phenomenon.
Conditions
Timeline
- Start date
- 2016-10-31
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
- First posted
- 2020-08-06
- Last updated
- 2020-08-06
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT04502355. Inclusion in this directory is not an endorsement.